iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed drug candidates include iCo-007, an anti-sense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; iCo-008 (Bertilimumab), a monoclonal antibody, which is in Phase II clinical trial to treat patients with moderate-to-severe ulcerative colitis; and iCo-009, an experimental oral formulation of Amphotericin B that is in pre-clinical stage for the treatment of systemic fungal infections and parasitical infections. The company has partnership arrangements with Isis Pharmaceuticals Inc. to develop and commercialize iCo-007; MedImmune Limited and Immune Pharmaceuticals Corp. to develop and commercialize iCo-008; and the University of British Columbia for the development of iCo-009, as well as a research collaboration agreement with Juvenile Diabetes Research Foundation (JDRF) to support the Phase II clinical trial of iCo-007. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.